Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9228033 | 0.80 | NPSR1 (0.54) | CTSANPSR1LMNAALDH1A1MAPT | |
| SCHEMBL6387359 | 0.80 | POLB (0.55) | CTSAMEN1KMT2ANPSR1LMNA | |
| SCHEMBL11093885 | 0.77 | HTT (0.47) | MEN1KMT2ANPSR1LMNAALDH1A1 | |
| SCHEMBL20577005 | 0.77 | TTR (0.48) | MEN1KMT2ANPSR1LMNAALDH1A1 | |
| SCHEMBL21723363 | 0.77 | HTT (0.47) | MEN1KMT2ANPSR1LMNAALDH1A1 | |
| SCHEMBL19420118 | 0.76 | EEF2K (0.48) | CTSAMEN1KMT2ATDP1FFAR1 | |
| SCHEMBL19420103 | 0.76 | EEF2K (0.48) | CTSAMEN1KMT2ATDP1FFAR1 | |
| SCHEMBL28120098 | 0.75 | HTT (0.45) | MEN1KMT2ANPSR1LMNAALDH1A1 | |
| SCHEMBL510313 | 0.75 | ALDH1A1 (0.51) | MEN1KMT2ANPSR1LMNAALDH1A1 | |
| SCHEMBL3451872 | 0.74 | ACHE (0.55) | NPSR1ALDH1A1TDP1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257547-B1 | 1,3-DISUBSTITUTED PYRROLIDINES AS ALPHA-2-ADRENOCEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7012085-B2 | 1,3 disubstituted pyrrolidines as α-2-adrenoceptor antagonists | NOVARTIS AG (CH) | 2006-03-14 | — | — | US | disclosed |
| US-20030008874-A1 | 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists | NOVARTIS AG (CH) | 2003-01-09 | — | — | US | disclosed |
| EP-1257547-A1 | 1,3-DISUBSTITUTED PYRROLIDINES AS ALPHA-2-ADRENOCEPTOR ANTAGONISTS | Novartis AG (CH) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001055132-A1 | 1,3-DISUBSTITUTED PYRROLIDINES AS ALPHA-2-ADRENOCEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008874-A1 | 1,3 disubstituted pyrrolidines as alpha -2- adrenoceptor antagonists | ADRB2, ADRB1, ADRA1A | CTSA 3427/4885MEN1 2704/4885KMT2A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.